Skip to main content

Advertisement

Table 1 Patient Characteristics

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

   Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43 Total n = 89
Age, years Median 68 66 67
  Range 40–80 56–80 40–80
Gender (n, %) Male 26 (57%) 18 (42%) 44 (49%)
  Female 20 (43%) 25 (58%) 45 (51%)
Stage III 3 (7%) 4 (9%) 7 (8%)
  IV 3 (7%) 1 (2%) 4 (4%)
  IVa 3 (7%) 4 (9%) 7 (8%)
  IVb 37 (80%) 34 (79%) 71 (80%)
KP score at screening 70 3 (7%) 2 (5%) 5 (6%)
  80 19 (41%) 18 (42%) 37 (42%)
  90 18 (39%) 17 (40%) 35 (40%)
  100 6 (13%) 6 (14%) 12 (13%)
  1. Abbreviation: KP, Karnofsky performance.